NCAM1 and acute myeloid leukemia: In addition to focusing on the independent prognostic value of CD56 expression, we should consider integrating this marker into a multidimensional immunophenotype or cytogenetic abnormalities for comprehensive analysis, which is more helpful to scientifically classify and evaluate the prognosis of children with AML.